Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GRI Bio Inc. (GRI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/29/2025: GRI (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22.5
1 Year Target Price $22.5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -71.39% | Avg. Invested days 37 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/29/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.88M USD | Price to earnings Ratio 0.02 | 1Y Target Price 22.5 |
Price to earnings Ratio 0.02 | 1Y Target Price 22.5 | ||
Volume (30-day avg) 2 | Beta -1.44 | 52 Weeks Range 1.10 - 22.95 | Updated Date 10/29/2025 |
52 Weeks Range 1.10 - 22.95 | Updated Date 10/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 90.8 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -98.68% | Return on Equity (TTM) -248.92% |
Valuation
Trailing PE 0.02 | Forward PE - | Enterprise Value -70850 | Price to Sales(TTM) - |
Enterprise Value -70850 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 2515305 | Shares Floating 2514827 |
Shares Outstanding 2515305 | Shares Floating 2514827 | ||
Percent Insiders 0.02 | Percent Institutions 1.46 |
Upturn AI SWOT
GRI Bio Inc.
Company Overview
History and Background
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering the development of therapies for inflammatory, fibrotic and autoimmune diseases. Founded in 2020, it aims to address unmet needs in these disease areas through novel immune cell-based approaches. GRI Bio went public through a SPAC merger. Significant milestones include advancing its lead programs through clinical trials and establishing partnerships to expand its research and development capabilities.
Core Business Areas
- Immuno-oncology: Developing novel immuno-oncology therapies by targeting novel immune checkpoints.
- Autoimmune Diseases: Creating innovative treatments for a range of autoimmune diseases.
- Fibrotic Diseases: Researching and developing therapeutic approaches to reverse the progression of Fibrotic Diseases.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry, including individuals with expertise in drug development, clinical trials, and regulatory affairs. Organizational structure involves departments for research, development, clinical operations, and business development.
Top Products and Market Share
Key Offerings
- GRI-0621: GRI-0621 is an oral small molecule being developed as a potential treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Market share data is not publicly available, as it is still in clinical trials. Competitors include Boehringer Ingelheim (Ofev), Roche (Esbriet), and other companies developing novel therapies for IPF.
- GRI-0803: GRI-0803 is another oral small molecule targeting inflammasome activation. It is currently in preclinical development. Market share data is not yet available as it is not yet launched. Competitors include companies with established inflammatory therapies, but since it targets inflammasomes, direct comparators are also in the early stages.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and dynamic, with significant investment in research and development. It is characterized by stringent regulatory requirements and extended timelines for drug development. Recent trends include a focus on personalized medicine, advanced therapies (gene and cell therapies), and digital health solutions.
Positioning
GRI Bio Inc. is positioning itself as an innovator in immune cell-based therapies for inflammatory, fibrotic, and autoimmune diseases. Its competitive advantage lies in its proprietary platform and novel targets.
Total Addressable Market (TAM)
The total addressable market for inflammatory, fibrotic and autoimmune diseases is substantial, estimated at over $100 billion globally. GRI Bio Inc. is focused on niche markets with high unmet needs, aiming to capture a significant share through innovative therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic targets
- Proprietary technology platform
- Experienced management team
- Focus on high unmet needs
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Early-stage company
- High R&D expenses
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Changes in healthcare policies
Competitors and Market Share
Key Competitors
- VRDN
- IMVT
- ALNY
Competitive Landscape
GRI Bio Inc. faces competition from both established pharmaceutical companies and smaller biotech firms. Its advantages include novel targets and a proprietary platform, while its disadvantages include limited financial resources and a shorter track record.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by the company's progress in advancing its pipeline and securing funding.
Future Projections: Future growth depends on the successful completion of clinical trials and potential regulatory approvals. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing GRI-0621 into clinical trials, expanding its research collaborations, and strengthening its intellectual property portfolio.
Summary
GRI Bio Inc. is an early-stage biopharmaceutical company with a promising pipeline of novel therapies for inflammatory, fibrotic, and autoimmune diseases. It has potential with its proprietary technology platform and experienced management team. The company needs to successfully complete clinical trials and secure financial resources. It also faces competition from larger, well-established pharmaceutical companies and clinical trial risks.
Similar Stocks
Sources and Disclaimers
Data Sources:
- GRI Bio Inc. SEC Filings
- Company Website
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is based on available estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRI Bio Inc.
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2021-02-10 | Co-Founder, CEO, President & Director Dr. W. Marc Hertz Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://www.gribio.com |
Full time employees 3 | Website https://www.gribio.com | ||
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.